ROSSARI452.00

Rossari Biotech Limited

· Chemicals
₹ CrorePeersNOCILHSCLNAVINFLUORDDEVPLSTIKCHEMPLASTSTATACHEMAARTIINDJGCHEMMcap ₹2,503 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ROSSARI
FY26
NOCIL
FY26
HSCL
FY26
NAVINFLUOR
FY26
Peer
Median
Valuation — at last close
P/E16.77×58.41×44.05×66.72×58.41× -71%
P/B1.88×1.83×7.04×11.24×7.04× -73%
EV/EBITDA9.80×28.87×35.32×41.29×35.32× -72%
Market Cap₹2,503 Cr₹3,248 Cr₹33,509 Cr₹44,680 Cr₹33,509 Cr -93%
Growth
Revenue CAGR 3Y13.11%-6.94%3.76%16.84%3.76% +249%
Revenue CAGR 5Y27.57%7.10%22.65%22.95%22.65% +22%
Net Income CAGR 3Y11.63%-28.02%51.80%20.93%20.93% -44%
Revenue YoY (latest Q)28.23%19.87%28.04%44.07%28.04% +1%
Net Income YoY (latest Q)4.46%60.83%27.36%107.67%60.83% -93%
Profitability
EBITDA Margin11.93%7.73%20.64%32.64%20.64% -42%
Net Income Margin6.23%4.27%16.20%20.02%16.20% -62%
Return on Common Equity11.19%3.14%15.78%16.69%15.78% -29%
Return on Capital Employed13.79%2.41%17.63%17.56%17.56% -21%
Return on Assets6.52%2.64%11.97%10.40%10.40% -37%
Credit & Quality
Total Debt/Equity0.31×0.00×0.16×0.31×0.16× +94%
Interest Coverage7.24×33.04×13.89×7.91×13.89× -48%
Scale — latest FY
Revenue / Total Income₹2,396 Cr₹1,303 Cr₹4,661 Cr₹3,314 Cr₹3,314 Cr -28%
Net Income₹149 Cr₹55.6 Cr₹755 Cr₹664 Cr₹664 Cr -78%
Total Assets₹2,289 Cr₹2,111 Cr₹6,306 Cr₹6,379 Cr₹6,306 Cr -64%
EPS₹26.95₹3.33₹15.08₹130.67₹15.08 +79%
Book Value per Share₹240.74₹106.18₹94.39₹775.53₹106.18 +127%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.